• Explore /
  • Poster
  • / Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study.

Lisocabtagene maraleucel (liso-cel) as second-line (2L) treatment (tx) for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): Patient-reported outcomes (PRO) from the phase 2 PILOT study.

Abstract Poster

Authors

Leo Gordon

Leo I. Gordon

Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL

Leo I. Gordon , Daanish Hoda , Ling Shi , Shien Guo , Fei Fei Liu , Julia Braverman , Ronald L. Dubowy , Lily Peng , Alison Sehgal

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Health Services Research and Quality Improvement

Track

Quality Care/Health Services Research

Sub Track

Quality Improvement

Clinical Trial Registration Number

NCT03483103

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 6567)

DOI

10.1200/JCO.2022.40.16_suppl.6567

Abstract #

6567

Poster Bd #

350

Abstract Disclosures

Similar Posters

First Author: Alison Sehgal

First Author: Alison R. Sehgal

First Author: Alicia K. Morgans

Poster

2021 ASCO Quality Care Symposium

Development of PRO-PMs assessing symptoms following completion of curative-intent chemotherapy.

Development of PRO-PMs assessing symptoms following completion of curative-intent chemotherapy.

First Author: Katherine Eresian Chenok